ArticleCancers2022

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan.

Hiroshi Nokihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.